The PROSPER and SPARTAN studies are impacting standard of care

The PROSPER and SPARTAN studies are impacting standard of care

obr

1 year
87 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer are impacting standard of care at Annual Meeting 2018.
Up Next Autoplay
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 40 minutes
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 50 minutes
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 1 hour
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
2 Views
Cancer-News 2 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
0 Views
Cleveland Clinic 2 hours
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 2 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
0 Views
Cleveland Clinic 2 hours
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
1 Views
Cleveland Clinic 3 hours
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
Category: News
2 Views
alexvarney 4 hours
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 18 hours